Absolute Lymphocyte Count Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP or R-CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.

摘要: Absolute lymphocyte count (ALC) recovery post-autologous stem cell transplantation has been documented as an independent predictor for survival in non-Hodgkin lymphoma. The effect of ALC on during standard CHOP or R-CHOP chemotherapy newly diagnosed diffuse large B lymphoma (DLBCL) is unknown. To participate the study, patients required to receive their full treatment with complete blood determinations at Mayo Clinic College Medicine. Of 1633 DLBCL cases seen Medicine between February 1994 through August 2004, 212 consecutive were eligible study. We study a prognostic factor progression-free (PFS) and overall (OS) treated least 3 cycles R-CHOP. 57% male median age was 66 years (range: 20 – 87); 42% had elevated LDH, only 11% PS 2 higher; 58% low stage (I II); 88% pts achieved response. evaluated beginning each cycle, focusing 1–3 month post sample. significantly correlated PFS OS, cycle 1 most when accounting inherent differences based (Rx) type (i.e. vs. R-CHOP) well high IPI (PFS: p = 0.0012; OS: 0.005). Also, 74 1,000 all three cycles, where there no significant relationship this incidence Rx type; associated higher (p 0.0007) OS 0.0006), even IPI. In 179 who 3-month post-Rx data, also 0.002) 0.0009), while still status. Achievement >= 0.0014) (0.003). Also note, different 0.008). summary, these data support hypothesis that critical role (immune) CHOP/R-CHOP DLBCL.